Helixmith Co

Helixmith Co Book Value per Share

The Book Value per Share of Helixmith Co (084990.KQ) as of Oct 21, 2026 is 3,021.39 KRW. In the previous year, Book Value per Share was 3,031.79 KRW — a change of -0.34% (lower).

Book Value per Share

3,021.39KRW

YoY

-0.34%

Last updated:

Book Value per Share of Helixmith Co is 2025 3,021.39 KRW. Book Value per Share of Helixmith Co was 2024 3,031.79 KRW. It decreases by -0.34% lower compared to the previous year.

The Helixmith Co Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
2,848.84 KRW
Jan 1, 2019
4,161.76 KRW
Jan 1, 2020
5,879.86 KRW
Jan 1, 2021
4,795.58 KRW
Jan 1, 2022
4,613.65 KRW
Jan 1, 2023
3,280.11 KRW
Jan 1, 2024
3,031.79 KRW
Jan 1, 2025
3,021.39 KRW
The Helixmith Co Book Value per Share history
YEARBook Value per ShareYoY
3,021.39KRW-0.34%
3,031.79KRW-7.57%
3,280.11KRW-28.90%
4,613.65KRW-3.79%
4,795.58KRW-18.44%
5,879.86KRW+41.28%
4,161.76KRW+46.09%
2,848.84KRW-18.60%
3,499.70KRW-3.79%
3,637.44KRW+154.37%
1,429.98KRW+0.20%
1,427.16KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Helixmith Co Stock analysis

What does Helixmith Co do? Helixmith Co., Ltd. generates revenue through its Natural Products Business segment, which develops and sells raw materials for functional materials and health functional foods under brands like Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment focuses on developing treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer therapies. Customers include companies in the health and pharmaceutical sectors seeking natural ingredients and specialized medical treatments. The company serves two distinct market segments: one for natural product raw materials and another for advanced biopharmaceutical solutions. The Natural Products Business segment targets clients requiring raw materials for functional materials and health functional foods, leveraging branded products Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment caters to healthcare providers and pharmaceutical firms developing treatments for specific medical conditions, including diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer applications. Both segments operate within the broader health and biotechnology industries, with the company's revenue streams derived from product sales across these specialized markets. Helixmith Co., Ltd. monetizes its research and development efforts through the commercialization of natural substance-based raw materials and biopharmaceutical treatments. The company's product portfolio includes Alex, Murphine, and Nimosin for the natural products market, while its biopharmaceutical segment offers treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer conditions. Revenue is generated from direct sales to businesses in the health, functional food, and pharmaceutical sectors, with no mention of additional revenue streams such as licensing or partnerships. Helixmith Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Helixmith Co stock

Book Value per Share of Helixmith Co is 3,021.39 KRW in 2025.

Book Value per Share of Helixmith Co changed from 3,031.79 KRW to 3,021.39 KRW, representing a -0.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Helixmith Co since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Helixmith Co

All Key Metrics — Helixmith Co